Customer Testimonials

Discover the impact of Xoft eBx on our customers' facilities and patients

Xoft Brain IORT

Marta Ortega, MD, NS, Cáceres University Hospital“We were encouraged by preliminary data supporting Xoft IORT for brain tumors, and we are impressed with the protocol of the GLIOX trial evaluating an innovative therapeutic approach to treat recurrent GBM. When we were offered the opportunity to treat patients with Xoft IORT, as well as the chance to potentially join the GLIOX trial, we immediately began using the new approach on patients with GBM and other tumor types. Although it is still early, results thus far are encouraging. This method offers hope for certain types of disease, as it may allow us to select patients for a treatment that could replace weeks of external beam radiotherapy (EBRT).”Naveed Wagle, MD
Associate Professor of Neurosciences at the Saint John’s Cancer Institute
“This is a significant milestone, not just for our institute, but also for patients with recurrent glioblastoma. The initiation of a clinical trial under normal circumstances is no small feat, but the COVID pandemic presented additional challenges that had to be overcome. It truly was an enormous achievement, and we are excited that we can now offer it to patients.”
Alexey Gaytan, MD, PhD, Neurosurgeon at the European Medical Center“Treatment options for patients with recurrent GBM are extremely limited. As such, we are encouraged by the interim results that demonstrate significant improvement in OS and locPFS in recurrent GBM patients with maximal safe resection plus Xoft Brain IORT compared to re-resection followed by various alternative adjuvant therapy options (mostly external beam re-irradiation plus chemotherapy). This innovative approach is equivalent to multiple sessions of external beam radiation therapy (EBRT), yet with minimized risk of radiation dose to neighboring healthy tissues. We encourage collaboration on further multidisciplinary, multicenter clinical trials as the initial data is promising.”Michael Howard, PhD, DABMP, RSO, Director of Oncology Services and Chief of Medical Physics at the Sarah Cannon Cancer Institute at the Parkridge Medical Center in Chattanooga, TN“New treatments for recurrent GBM are greatly needed, and local recurrence is often inevitable after the first round of radiation therapy due to resistance to radiation. However, clinical results are beginning to reveal that Xoft Brain IORT shows significant promise for treating recurrent GBM, and we are eager to begin evaluating its feasibility and safety on patients here at the Sarah Cannon Cancer Institute.”Santosh Kesari, MD, PhD,
Director of Neuro-oncology Chair and Professor, Department of Translational Neurosciences at Saint John's Cancer Institute in Santa Monica, CA
“GBM is one of the most aggressive cancers with very poor survival and innovative approaches are needed. We are eager to open this international Phase II multi-center study using Xoft IORT as a potential new approach to local control of this devastating disease. In particular, if the results of this Phase II medical device trial confirm previously reported results, this innovative technology could rapidly be adopted since it is already cleared for use by the FDA for treatment of cancer anywhere in the body.”
Alexey Krivoshapkin, MD, PhD, Neurosurgeon at the European Medical Center (EMC) in Moscow, Russia“We are encouraged by the promising results we’ve seen using IORT to deliver the required prescribed single focal dose that is equal to multiple sessions of EBRT while minimizing radiation dose to neighboring healthy tissue for the treatment of recurrent GBM. While our findings concluded feasibility, more clinical trials are warranted, and we whole-heartedly applaud the collaborative efforts.”Mehran Yusuf, MD, Radiation Oncologist at the James Graham Brown Cancer Center at the University of Louisville"We’ve treated four patients in our trial and our initial experience suggests IORT using the Xoft eBx system for treatment of large, resected brain metastases is well tolerated without unexpected early adverse treatment effects.”

Xoft Breast IORT

Martin Tejedor, MD PhD, Chairman of Aragon Radiation Oncology Multihospital Clinical Unit  (UCMORA)“Traditionally, HDR intracavitary brachytherapy using Iridium 192 seeds has been used for patients with endometrial cancer, but the recent development of electronic brachytherapy based on a miniaturized X-ray source has important advantages over HDR. The ability to precisely target cancer cells while preserving surrounding healthy tissue has significantly improved patient outcomes. Our study found long-term advantages with Xoft eBx, providing the same benefits as traditional methods with a reduction in radiation toxicity to at-risk organs.”A.M. Nisar Syed, MD, Radiation Oncology, Todd Cancer Institute, MemorialCare Long Beach Medical Center“Our ongoing research with the Xoft System for early-stage breast cancer corroborates the mounting long-term evidence supporting 50 kV IORT as a treatment option that is as effective as weeks of daily radiation fractions. Xoft IORT can spare patients who are candidates from the need to make multiple trips to the hospital for treatment, with the added benefit of fewer side effects and comparable recurrence rates. It not only offers added convenience for women, especially those living in remote areas who must travel great distances for radiation, it may be particularly comforting for women who want to minimize their potential risk of COVID-19 exposure.”Reyes Ibanez, MD, Miguel Servet University Hospital in Zaragoza“The use of Xoft IORT for multiple cancers, including early-stage breast cancer, gynecological cancers, and nonmelanoma skin cancers, is quickly gaining appreciation globally due to promising data and results substantiating its feasibility as well as real-life treatment experience. We have used the Xoft System for the treatment of multiple types of tumors at our facility, including breast, skin, gynecological, and now brain tumors. The precision and flexibility afforded by Xoft can spare patients from numerous trips to the hospital and has helped position our facility as a leader in cancer care by offering the versatility to treat a broad range of cancers.”“We’re very familiar with the Xoft eBx System, as our hospital has performed hundreds of treatments with the technology for breast and gynecological applications. As such, we are confident we will treat more metastasis in the future using IORT.”

Xoft Skin eBx

Sidney P. Smith, MD, Mohs Surgeon, Chief Executive Officer, Georgia Skin and Cancer Clinic“We recently decided to adopt the Xoft System because it is a clinically proven treatment option for NMSC that offers patients the ability to complete a course of therapy in fewer treatments, compared to alternative treatments. While Mohs surgery certainly has a high cure rate, there are some patients for whom Xoft Skin eBx may be more suitable. For example, patients who are on blood thinners, or who have lesions in difficult-to-treat areas, such as the face, head, or neck. Patients with multiple NMSC lesions may also just reach a point of excision fatigue, and in these cases, they may prefer Xoft skin eBx, as it offers a painless, noninvasive approach to treatment, which yields excellent clinical and cosmetic results.”

Sidney P. Smith, MD, Mohs Surgeon, Chief Executive Officer, Georgia Skin and Cancer Clinic

© Xoft, a subsidiary of iCAD, Inc. All rights reserved. Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are registered trademarks of iCAD, Inc.  Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.